Pathstone Family Office’s AstraZeneca AZN Stock Holding History

Pathstone Family Office’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$4.38M	Buy	32,372 +7,482	+30%	+$1.02M	0.03%	297
2023 Q2	$3.57M	Sell	24,890 -1,642	-6%	-$242K	0.05%	213
2023 Q1	$3.68M	Sell	26,532 -34,341	-56%	-$4.62M	0.06%	183
2022 Q4	$8.97M	Buy	60,873 +14,357	+31%	+$1.8M	0.08%	187
2022 Q3	$5.12M	Buy	46,516 +33,934	+270%	+$4.3M	0.05%	229
2022 Q2	$1.66M	Buy	12,582 +1,619	+15%	+$212K	0.04%	237
2022 Q1	$1.46M	Sell	10,963 -200	-2%	-$24K	0.03%	238
2021 Q4	$1.3M	Buy	11,163 +812	+8%	+$95.5K	0.03%	273
2021 Q3	$1.24M	Buy	10,351 +2,267	+28%	+$264K	0.04%	237
2021 Q2	$968K	Buy	8,084 +2,134	+36%	+$234K	0.03%	278
2021 Q1	$592K	Buy	5,950 +4,703	+377%	+$473K	0.02%	310
2020 Q4	$125K	Buy	1,247 +992	+389%	+$105K	0.01%	344
2020 Q3	$28K	Hold	255	–	–	﹤0.01%	434
2020 Q2	$27K	Hold	255	–	–	﹤0.01%	386
2020 Q1	$23K	Sell	255 -375	-60%	-$35.3K	﹤0.01%	399
2019 Q4	$627K	Buy	630 +375	+147%	+$35.3K	0.01%	256
2019 Q3	$23K	Hold	255	–	–	﹤0.01%	375
2019 Q2	$21K	Hold	255	–	–	﹤0.01%	435
2019 Q1	$21K	Buy	+255	New	+$20.1K	﹤0.01%	426
2016 Q3	–	Sell	-125	Closed	-$8K	–	200
2016 Q2	$8K	Buy	+125	New	+$7.26K	0.01%	155

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pathstone Family Office's AZN Position: Q3 2023 in Review

Pathstone Family Office increased its AstraZeneca (AZN) stake by 30% in Q3 2023, buying an estimated $1.02M and bringing the position to 32,372 shares worth $4.38M. The position accounts for 0.03% of the portfolio, ranked #297.

Pathstone Family Office first reported a position in AZN in Q2 2016 and has held it in 20 quarters since. The position peaked at $8.97M in Q4 2022. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Pathstone Family Office held 32,372 shares of AstraZeneca worth $4.38M as of Q3 2023.
Pathstone Family Office bought 7,482 AstraZeneca shares in Q3 2023, an estimated $1.02M.
AstraZeneca made up 0.03% of Pathstone Family Office's portfolio in Q3 2023, its #297 holding.
Pathstone Family Office first reported a position in AstraZeneca in Q2 2016 and has held it in 20 quarters since.
Pathstone Family Office's AstraZeneca position peaked at $8.97M in Q4 2022.
1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.